PD1-PDL1-IN 1 TFA

• CAT Number: I041437
• Molecular Formula: C16H24F3N7O8
• Molecular Weight: 499.40
• Purity: ≥95%
• Synonyms: (2S,3R)-2-[[(1S)-3-amino-3-oxo-1-(3-piperazin-1-yl-1,2,4-oxadiazol-5-yl)propyl]carbamoylamino]-3-hydroxybutanoic acid;2,2,2-trifluoroacetic acid
• IUPAC Name: (2S)-2-[[(1S)-3-amino-3-oxo-1-(3-piperazin-1-yl-1,2,4-oxadiazol-5-yl)propyl]carbamoylamino]-3-hydroxybutanoic acid;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C14H23N7O6.C2HF3O2/c1-7(22)10(12(24)25)18-14(26)17-8(6-9(15)23)11-19-13(20-27-11)21-4-2-16-3-5-21;3-2(4,5)1(6)7/h7-8,10,16,22H,2-6H2,1H3,(H2,15,23)(H,24,25)(H2,17,18,26);(H,6,7)/t7?,8-,10-;/m0./s1
• InChIKey: JHTXTLJOVWXUDK-LEFOPYBQSA-N
• SMILES: CC([C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NC(=NO1)N2CCNCC2)O.C(=O)(C(F)(F)F)O

PD1-PDL1-IN 1 TFA（Cat No.:I041437）is a small-molecule inhibitor that targets the PD-1/PD-L1 signaling pathway, which plays a critical role in immune evasion by tumors. This compound is designed to block the interaction between PD-1 on immune cells and PD-L1 on tumor cells, thereby enhancing the immune system’s ability to recognize and attack cancer cells. The “TFA” in the name refers to trifluoroacetic acid, a solvent used in the synthesis and purification process. PD1-PDL1-IN 1 TFA is primarily used in cancer immunotherapy research and clinical trials aimed at improving anti-tumor immunity.